COMMUNICATION

Comprehensive analysis of the N and C terminus of endogenous serum peptides reveals a highly conserved cleavage site pattern derived from proteolytic enzymes

Expand
  • CAS Key Lab of Separation Sciences for Analytical Chemistry, National Chromatographic Research and Analysis Center, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China

Received date: 12 Apr 2012

Accepted date: 07 May 2012

Published date: 01 Sep 2012

Abstract

The human serum proteome is closely associated with the state of the body. Endogenous peptides derived from proteolytic enzymes cleaving on serum proteins are widely studied due to their potential application in disease-specific marker discovery. However, the reproducibility of peptidome analysis of endogenous peptides is significantly influenced by the proteolytic enzymes within body fluids, thereby limiting the clinical use of the endogenous peptides. We comprehensively investigated the N and C terminus of endogenous peptides using peptidomics. The cleavage site patterns of the N and C terminus and adjacent sites from all the identified endogenous peptides were highly conserved under different sample preparation conditions, including long-term incubation at 37°C and pretreatment with repeated freeze-thaw cycles. Furthermore, a distinguishable cleavage site pattern was obtained when a different disease serum was analyzed. The conserved cleavage site pattern derived from proteolytic enzymes holds potential in highly specific disease diagnosis.

Cite this article

Fangjun Wang, Jun Zhu, Lianghai Hu, Hongqiang Qin, Mingliang Ye, Hanfa Zou . Comprehensive analysis of the N and C terminus of endogenous serum peptides reveals a highly conserved cleavage site pattern derived from proteolytic enzymes[J]. Protein & Cell, 2012 , 3(9) : 669 -674 . DOI: 10.1007/s13238-012-2934-4

References

[1] Cox, J. and Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotech 26, 1367-1372 .10.1038/nbt.1511
[2] Diamandis, E.P. (2006). Peptidomics for cancer diagnosis: present and future. J Proteome Res 5, 2079-2082 .10.1021/pr060225u
[3] Doucet, A., Butler, G.S., Rodriguez, D., Prudova, A., and Overall, C.M. (2008). Metadegradomics toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. Mol Cell Proteomics 7, 1925-1951 .10.1074/mcp.R800012-MCP200
[4] Koomen, J.M., Li, D.H., Xiao, L.C., Liu, T.C., Coombes, K.R., Abbruzzese, J., and Kobayashi, R. (2005). Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 4, 972-981 .10.1021/pr050046x
[5] Kresge, C.T., Leonowicz, M.E., Roth, W.J., Vartuli, J.C., and Beck, J.S. (1992). Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 359, 710-712 .10.1038/359710a0
[6] Nilsson, T., Mann, M., Aebersold, R., Yates, J.R., Bairoch, A., and Bergeron, J.J.M. (2010). Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Meth 7, 681-685 .10.1038/nmeth0910-681
[7] Rai, A.J., Gelfand, C.A., Haywood, B.C., Warunek, D. J., Yi, J., Schuchard, M.D., Mehigh, R.J., Cockrill, S.L., Scott, G.B. I, Tammen, H., . (2005). HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5, 3262-3277 .10.1002/pmic.200401245
[8] Ransohoff, D.F. (2005). Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 5, 142-149 .10.1038/nrc1550
[9] Schrader, M. and Schulz-Knappe, P. (2001). Peptidomics technologies for human body fluids. Trends Biotechnol 19, 55-60 .10.1016/S0167-7799(01)00010-5
[10] Soloviev, M. and Finch, P. (2006). Peptidomics: bridging the gap between proteome and metabolome. Proteomics 6, 744-747 .10.1002/pmic.200500878
[11] Tian, R.J., Zhang, H., Ye, M.L., Jiang, X.G., Hu, L.H., Li, X., Bao, X.H., and Zou, H.F. (2007). Selective extraction of peptides from human plasma by highly ordered mesoporous silica particles for peptidome analysis. Angew Chem Int Ed 46, 962-965 .10.1002/anie.200603917
[12] Villanueva, J., Philip, J., Chaparro, C.A., Li, Y.B., Toledo-Crow, R., DeNoyer, L., Fleisher, M., Robbins, R.J., and Tempst, P. (2005). Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 4, 1060-1072 .10.1021/pr050034b
[13] Villanueva, J., Shaffer, D.R., Philip, J., Chaparro, C.A., Erdjument- Bromage, H., Olshen, A.B., Fleisher, M., Lilja, H., Brogi, E., Boyd, J., Sanchez-Carbayo, M., Holland, E.C., Cordon-Cardo, C., Scher, H.I., and Tempst, P. (2006). Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116, 271-284 .10.1172/JCI26022
[14] Wang, F.J., Chen, R., Zhu, J., Sun, D.G., Song, C.X., Wu, Y.F., Ye, M.L., Wang, L.M., and Zou, H.F. (2010). A fully automated system with online sample loading, isotope dimethyl labeling and multidimensional separation for high-throughput quantitative proteome analysis. Anal Chem 82, 3007-3015 .10.1021/ac100075y
[15] West-Nielsen, M., H?gdall, E.V., Marchiori, E., H?gdall, C.K., Schou, C., and Heegaard, N.H.H. (2005). Sample handling for mass spectrometric proteomic investigations of human sera. Anal Chem 77, 5114-5123 .10.1021/ac050253g
[16] Zhu, J., Wang, F.J., Dong, X.L., Ye, M.L., and Zou, H.F. (2010). A strategy with label-free quantification of the targeted peptides for quantitative peptidome analysis of human serum. Sci Chin A-Chem 53, 759-767 .10.1007/s11426-010-0127-7
Options
Outlines

/